Successful Treatment of Nivolumab and Ipilimumab Triggered Type 1 Diabetes by Using Sodium-glucose Transporter 2 Inhibitor: a Case Report and Systematic Review

Overview

Journal Front Public Health

Specialty Public Health

Date 2023 Dec 18

PMID 38106883

Authors

Makoto Fujiwara

Masaru Shimizu

Tatsuya Okano

Yuko Maejima

Kenju Shimomura

Affiliations

Soon will be listed here.

Abstract

Objective: Checkpoint inhibitors (CPIs) can trigger complications related to the autoimmune process such as CPI-triggered diabetes mellitus. The typical treatment for CPI-triggered diabetes is insulin, but a detailed therapeutic method has not yet been established. To prevent severe symptoms and mortality of diabetic ketoacidosis in advanced-stage cancer patients, the establishment of effective treatment of CPI-triggered diabetes, other than insulin therapy, is required.

Methods: We present a case of a 76-year-old man with CPI-triggered diabetes who was treated with nivolumab and ipilimumab for lung cancer. We also conducted a systematic review of 48 case reports of type 1 diabetes associated with nivolumab and ipilimumab therapy before June 2023.

Results: The patient's hyperglycemia was not sufficiently controlled by insulin therapy, and after the remission of ketoacidosis, the addition of a sodium-glucose transporter (SGLT) 2 inhibitor, dapagliflozin, improved glycemic control. Most of the reported nivolumab/ipilimumab-induced type 1 diabetes was treatable with insulin, but very few cases required additional oral anti-diabetic agents to obtain good glucose control.

Conclusion: Although SGLT2 inhibitors have been reported to have adverse effects on ketoacidosis, recent studies indicate that the occurrence of ketoacidosis is relatively rare. Considering the pathological mechanism of CPI-triggered diabetes, SGLT2 inhibitors could be an effective choice if they are administered while carefully monitoring the patient's ketoacidosis.

Citing Articles

The Double-Edged Sword of Immunotherapy-Durvalumab-Induced Polyendocrinopathy-Case Report.

Blazowska O, Strozna K, Dancewicz H, Zygmunciak P, Zgliczynski W, Mrozikiewicz-Rakowska B J Clin Med. 2024; 13(21).

PMID: 39518461 PMC: 11546499. DOI: 10.3390/jcm13216322.

Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.

Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C Basic Res Cardiol. 2024; 120(1):241-262.

PMID: 38935171 PMC: 11790819. DOI: 10.1007/s00395-024-01059-9.

References

Telo G, Carvalhal G, Cauduro C, Webber V, Barrios C, Fay A . Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol. 2017; 28(1):191-192. DOI: 10.1093/annonc/mdw447. View

Sznol M, Postow M, Davies M, Pavlick A, Plimack E, Shaheen M . Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017; 58:70-76. DOI: 10.1016/j.ctrv.2017.06.002. View

Godwin J, Jaggi S, Sirisena I, Sharda P, Rao A, Mehra R . Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017; 5:40. PMC: 5433051. DOI: 10.1186/s40425-017-0245-2. View

Tsang V, McGrath R, Clifton-Bligh R, Scolyer R, Jakrot V, Guminski A . Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. J Clin Endocrinol Metab. 2019; 104(11):5499-5506. DOI: 10.1210/jc.2019-00423. View

Gauci M, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N . Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother. 2017; 66(11):1399-1410. PMC: 11028556. DOI: 10.1007/s00262-017-2033-8. View

Boswell L, Casals G, Blanco J, Jimenez A, Aya F, de Hollanda A . Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report. J Diabetes Investig. 2021; 12(12):2263-2266. PMC: 8668074. DOI: 10.1111/jdi.13604. View

Clotman K, Janssens K, Specenier P, Weets I, De Block C . Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9):3144-3154. DOI: 10.1210/jc.2018-00728. View

Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R . A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia. Intern Med. 2019; 58(19):2825-2830. PMC: 6815891. DOI: 10.2169/internalmedicine.2780-19. View

Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P . Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol. 2019; 26(1):e111-e114. PMC: 6380640. DOI: 10.3747/co.26.4151. View

10.

Miyoshi Y, Ogawa O, Oyama Y . Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. Tohoku J Exp Med. 2016; 239(2):155-8. DOI: 10.1620/tjem.239.155. View

11.

Teramoto Y, Nakamura Y, Asami Y, Imamura T, Takahira S, Nemoto M . Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol. 2016; 44(5):605-606. DOI: 10.1111/1346-8138.13486. View

12.

Khunti K, Aroda V, Bhatt D, Bozkurt B, Buse J, Heerspink H . Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022; 24(11):2071-2080. DOI: 10.1111/dom.14805. View

13.

Keerty D, Das M, Hallanger-Johnson J, Haynes E . Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy. Cureus. 2020; 12(9):e10632. PMC: 7584305. DOI: 10.7759/cureus.10632. View

14.

Ribas A . Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015; 373(16):1490-2. DOI: 10.1056/NEJMp1510079. View

15.

Palmer B, Clegg D . Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clin J Am Soc Nephrol. 2021; 16(8):1284-1291. PMC: 8455044. DOI: 10.2215/CJN.17621120. View

16.

Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24. DOI: 10.1093/intimm/dxm057. View

17.

Byun D, Wolchok J, Rosenberg L, Girotra M . Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13(4):195-207. PMC: 5629093. DOI: 10.1038/nrendo.2016.205. View

18.

Munakata W, Ohashi K, Yamauchi N, Tobinai K . Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. 2016; 105(3):383-386. DOI: 10.1007/s12185-016-2101-4. View

19.

Omodaka T, Kiniwa Y, Sato Y, Suwa M, Sato M, Yamaguchi T . Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab. J Dermatol. 2018; 45(10):e289-e290. DOI: 10.1111/1346-8138.14331. View

20.

Brahmer J, Lacchetti C, Thompson J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018; 14(4):247-249. DOI: 10.1200/JOP.18.00005. View